drugset
drugset / Trial / NCT02362516

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

NCT02362516 ↗

Phase 1 Completed 25 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the exposure of BI 425809 in cerebrospinal fluid relative to plasma as well as safety and tolerability, and to evaluate the effect of different doses of BI 425809 on biomarkers levels in cerebrospinal fluid.

Timeline

Start
2015-02-23
Primary completion
2015-06-19
Completion
2015-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 425809 Unknown 5 mg Oral
Subject BI 425809 Unknown 10 mg Oral
Subject BI 425809 Unknown 25 mg Oral
Subject BI 425809 Unknown 50 mg Oral

Indications

No indication recorded.